|
EP1519714B1
(en)
|
2002-06-28 |
2010-10-20 |
Protiva Biotherapeutics Inc. |
Method and apparatus for producing liposomes
|
|
CA2532228C
(en)
*
|
2003-07-16 |
2017-02-14 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
|
CN101346393B
(zh)
|
2005-11-02 |
2015-07-22 |
普洛体维生物治疗公司 |
修饰的siRNA分子及其应用
|
|
ES2535419T3
(es)
*
|
2007-12-27 |
2015-05-11 |
Protiva Biotherapeutics Inc. |
Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
CA2740000C
(en)
|
2008-10-09 |
2017-12-12 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
CN111808084A
(zh)
|
2008-11-10 |
2020-10-23 |
阿布特斯生物制药公司 |
用于递送治疗剂的新型脂质和组合物
|
|
EP2449106B1
(en)
*
|
2009-07-01 |
2015-04-08 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
WO2011000107A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
EP3494963A1
(en)
*
|
2009-12-18 |
2019-06-12 |
The University of British Columbia |
Methods and compositions for delivery of nucleic acids
|
|
WO2011136369A1
(ja)
*
|
2010-04-28 |
2011-11-03 |
協和発酵キリン株式会社 |
カチオン性脂質
|
|
KR101773643B1
(ko)
|
2010-04-28 |
2017-08-31 |
교와 핫꼬 기린 가부시키가이샤 |
양이온성 지질
|
|
US20130123338A1
(en)
|
2010-05-12 |
2013-05-16 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
EP2591114B1
(en)
|
2010-07-06 |
2016-06-08 |
GlaxoSmithKline Biologicals SA |
Immunisation of large mammals with low doses of rna
|
|
ES2646669T3
(es)
|
2010-07-06 |
2017-12-14 |
Glaxosmithkline Biologicals Sa |
Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
|
|
MX342608B
(es)
|
2010-07-06 |
2016-10-06 |
Novartis Ag * |
Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion.
|
|
ES2557382T3
(es)
|
2010-07-06 |
2016-01-25 |
Glaxosmithkline Biologicals Sa |
Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
LT4226941T
(lt)
|
2010-08-31 |
2025-01-10 |
Glaxosmithkline Biologicals Sa |
Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
|
|
EP2625189B1
(en)
|
2010-10-01 |
2018-06-27 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012051211A2
(en)
|
2010-10-11 |
2012-04-19 |
Novartis Ag |
Antigen delivery platforms
|
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
WO2012162210A1
(en)
*
|
2011-05-26 |
2012-11-29 |
Merck Sharp & Dohme Corp. |
Ring constrained cationic lipids for oligonucleotide delivery
|
|
EP2729165B1
(en)
|
2011-07-06 |
2017-11-08 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
DE19216461T1
(de)
|
2011-10-03 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
|
|
WO2013086354A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
CA3018046A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
WO2013093891A1
(en)
*
|
2011-12-22 |
2013-06-27 |
Nuvo Research Gmbh |
Liposomal chlorite or chlorate compositions
|
|
US9035039B2
(en)
*
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
EP2817287B1
(en)
*
|
2012-02-24 |
2018-10-03 |
Arbutus Biopharma Corporation |
Trialkyl cationic lipids and methods of use thereof
|
|
BR112014024131A2
(pt)
|
2012-03-29 |
2017-07-25 |
Shire Human Genetic Therapies |
lipídios catiônicos ionizáveis
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
CN104411338A
(zh)
|
2012-04-02 |
2015-03-11 |
现代治疗公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
HK1207977A1
(en)
|
2012-04-25 |
2016-02-19 |
Trustees Of Tufts College |
Silk microspheres and methods for surface lubrication
|
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
|
EP3031921B1
(en)
|
2012-12-12 |
2025-03-12 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
US20160002628A1
(en)
*
|
2013-03-11 |
2016-01-07 |
Georgia Tech Research Corporation |
Methods and compositions for managing vascular conditions
|
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
CN105683379A
(zh)
|
2013-06-17 |
2016-06-15 |
布罗德研究所有限公司 |
用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化
|
|
RU2716420C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
|
|
MX374532B
(es)
|
2013-06-17 |
2025-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
|
|
JP6620093B2
(ja)
*
|
2013-07-23 |
2019-12-11 |
アービュートゥス バイオファーマ コーポレイションＡｒｂｕｔｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐｏｒａｔｉｏｎ |
メッセンジャーｒｎａを送達するための組成物及び方法
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
EP3041934A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
SI3071696T1
(sl)
|
2013-11-22 |
2019-11-29 |
Mina Therapeutics Ltd |
C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
|
|
SG10201804975PA
(en)
|
2013-12-12 |
2018-07-30 |
Broad Inst Inc |
Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
|
|
JP7103750B2
(ja)
|
2013-12-12 |
2022-07-20 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
|
|
EP3470089A1
(en)
|
2013-12-12 |
2019-04-17 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
JP6712948B2
(ja)
|
2013-12-12 |
2020-06-24 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法
|
|
CN106536056B
(zh)
|
2014-06-13 |
2021-07-16 |
儿童医学中心公司 |
分离线粒体的产品和方法
|
|
HUE060907T2
(hu)
|
2014-06-25 |
2023-04-28 |
Acuitas Therapeutics Inc |
Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
|
|
EP3160448B1
(en)
*
|
2014-06-26 |
2025-08-06 |
Ramot at Tel-Aviv University Ltd. |
Liposomal formulations for delivery of nucleic acids
|
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3171895A1
(en)
|
2014-07-23 |
2017-05-31 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
WO2016028682A1
(en)
|
2014-08-17 |
2016-02-25 |
The Broad Institute Inc. |
Genome editing using cas9 nickases
|
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
EP3201338B1
(en)
|
2014-10-02 |
2021-11-03 |
Arbutus Biopharma Corporation |
Compositions and methods for silencing hepatitis b virus gene expression
|
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
EP3234192B1
(en)
|
2014-12-19 |
2021-07-14 |
The Broad Institute, Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
WO2016197132A1
(en)
|
2015-06-04 |
2016-12-08 |
Protiva Biotherapeutics Inc. |
Treating hepatitis b virus infection using crispr
|
|
WO2016205745A2
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
|
AU2016279077A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
|
TWI906646B
(zh)
|
2015-06-18 |
2025-12-01 |
美商博得學院股份有限公司 |
降低脫靶效應的ｃｒｉｓｐｒ酶突變
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
PT3313829T
(pt)
|
2015-06-29 |
2024-07-08 |
Acuitas Therapeutics Inc |
Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
|
|
WO2017019891A2
(en)
*
|
2015-07-29 |
2017-02-02 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing hepatitis b virus gene expression
|
|
WO2017031370A1
(en)
|
2015-08-18 |
2017-02-23 |
The Broad Institute, Inc. |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
|
JP6948313B6
(ja)
|
2015-09-17 |
2022-01-14 |
モデルナティエックス インコーポレイテッド |
治療剤の細胞内送達のための化合物および組成物
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
CN116814590A
(zh)
|
2015-10-22 |
2023-09-29 |
布罗德研究所有限公司 |
Vi-b型crispr酶和系统
|
|
AU2016341309A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Cancer vaccines
|
|
AU2016342045A1
(en)
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
EP4011451A1
(en)
|
2015-10-22 |
2022-06-15 |
ModernaTX, Inc. |
Metapneumovirus mrna vaccines
|
|
EP3368687B1
(en)
|
2015-10-27 |
2021-09-29 |
The Broad Institute, Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
|
HRP20230209T1
(hr)
|
2015-10-28 |
2023-04-14 |
Acuitas Therapeutics Inc. |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
US11903974B2
(en)
|
2015-11-30 |
2024-02-20 |
Flagship Pioneering Innovations V, Inc. |
Methods and compositions relating to chondrisomes from cultured cells
|
|
PL3386484T3
(pl)
|
2015-12-10 |
2022-07-25 |
Modernatx, Inc. |
Kompozycje i sposoby dostarczania środków terapeutycznych
|
|
US12110490B2
(en)
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
LT3394030T
(lt)
|
2015-12-22 |
2022-04-11 |
Modernatx, Inc. |
Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
|
|
PL3394093T3
(pl)
|
2015-12-23 |
2022-05-16 |
Modernatx, Inc. |
Metody stosowania polinukleotydów kodujących ligand ox40
|
|
MA43587A
(fr)
|
2016-01-10 |
2018-11-14 |
Modernatx Inc |
Arnm thérapeutiques codant pour des anticorps anti-ctla-4
|
|
WO2017124037A1
(en)
|
2016-01-15 |
2017-07-20 |
The Children's Medical Center Corporation |
Therapeutic use of mitochondria and combined mitochondrial agents
|
|
AU2017257274B2
(en)
|
2016-04-19 |
2023-07-13 |
Massachusetts Institute Of Technology |
Novel CRISPR enzymes and systems
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
KR20260004568A
(ko)
|
2016-04-19 |
2026-01-08 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규한 crispr 효소 및 시스템
|
|
CN109642231A
(zh)
|
2016-06-17 |
2019-04-16 |
博德研究所 |
Vi型crispr直向同源物和系统
|
|
US12595478B2
(en)
|
2016-06-29 |
2026-04-07 |
The Broad Institute, Inc. |
Crispr-Cas systems having destabilization domain
|
|
CN109563511A
(zh)
|
2016-06-30 |
2019-04-02 |
阿布特斯生物制药公司 |
用于递送信使rna的组合物和方法
|
|
EP4485466A3
(en)
|
2016-08-17 |
2025-04-02 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
WO2018035387A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
EP3500294A4
(en)
|
2016-08-22 |
2020-07-29 |
Arbutus Biopharma Corporation |
ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
US12499971B2
(en)
|
2016-09-28 |
2025-12-16 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
US12447213B2
(en)
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
EP3532103B1
(en)
|
2016-10-26 |
2025-12-03 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
EP4186888B1
(en)
|
2017-03-15 |
2025-11-26 |
ModernaTX, Inc. |
Compound and compositions for intracellular delivery of therapeutic agents
|
|
CA3055653A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
JP2020511141A
(ja)
|
2017-03-15 |
2020-04-16 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
新規Ｃａｓ１３ｂオルソログＣＲＩＳＰＲ酵素及び系
|
|
WO2018170322A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
EP3596112A2
(en)
|
2017-03-17 |
2020-01-22 |
Newcastle University |
Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
|
|
AU2018251801B2
(en)
|
2017-04-12 |
2024-11-07 |
Massachusetts Institute Of Technology |
Novel type VI CRISPR orthologs and systems
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
WO2018191719A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipid delivery of therapeutic agents to adipose tissue
|
|
WO2018191750A2
(en)
|
2017-04-14 |
2018-10-18 |
The Broad Institute Inc. |
Novel delivery of large payloads
|
|
CN110799492B
(zh)
|
2017-04-28 |
2023-06-27 |
爱康泰生治疗公司 |
用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
|
|
US11591601B2
(en)
|
2017-05-05 |
2023-02-28 |
The Broad Institute, Inc. |
Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
|
|
CA3062426A1
(en)
|
2017-05-08 |
2018-11-15 |
Flagship Pioneering Innovations V, Inc. |
Compositions for facilitating membrane fusion and uses thereof
|
|
JP7285220B2
(ja)
|
2017-05-18 |
2023-06-01 |
モデルナティエックス インコーポレイテッド |
連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
|
|
WO2018213726A1
(en)
|
2017-05-18 |
2018-11-22 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
IL271275B1
(en)
|
2017-06-13 |
2026-04-01 |
Flagship Pioneering Innovations V Inc |
Preparations containing croons and their uses
|
|
WO2018232120A1
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
EP3638292A1
(en)
|
2017-06-14 |
2020-04-22 |
ModernaTX, Inc. |
Polynucleotides encoding coagulation factor viii
|
|
MA49421A
(fr)
|
2017-06-15 |
2020-04-22 |
Modernatx Inc |
Formulations d'arn
|
|
CA3073020A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
EP4501322A3
(en)
|
2017-08-17 |
2025-04-16 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
EP3675817A1
(en)
|
2017-08-31 |
2020-07-08 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
WO2019048632A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
|
|
US20200208152A1
(en)
|
2017-09-08 |
2020-07-02 |
Mina Therapeutics Limited |
Stabilized sarna compositions and methods of use
|
|
AU2018338318B2
(en)
|
2017-09-21 |
2022-12-22 |
Massachusetts Institute Of Technology |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
WO2019071054A1
(en)
|
2017-10-04 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS
|
|
WO2019135816A2
(en)
|
2017-10-23 |
2019-07-11 |
The Broad Institute, Inc. |
Novel nucleic acid modifiers
|
|
WO2019089803A1
(en)
|
2017-10-31 |
2019-05-09 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
|
ES3062820T3
(en)
|
2017-11-08 |
2026-04-14 |
L E A F Holdings Group Llc |
Platinum complexes and uses thereof
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
WO2019126709A1
(en)
|
2017-12-22 |
2019-06-27 |
The Broad Institute, Inc. |
Cas12b systems, methods, and compositions for targeted dna base editing
|
|
EP3749318A4
(en)
|
2018-02-07 |
2022-07-06 |
L.E.A.F Holdings Group LLC |
GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
|
|
WO2019157129A1
(en)
|
2018-02-07 |
2019-08-15 |
L.E.A.F. Holdings Group Llc |
Alpha polyglutamated pralatrexate and uses thereof
|
|
CA3090389A1
(en)
|
2018-02-07 |
2019-08-15 |
L.E.A.F. Holdings Group Llc |
Alpha polyglutamated raltitrexed and uses thereof
|
|
WO2019157145A1
(en)
|
2018-02-07 |
2019-08-15 |
L.E.A.F. Holdings Group Llc |
Gamma polyglutamated pemetrexed and uses thereof
|
|
US12310966B2
(en)
|
2018-02-07 |
2025-05-27 |
L.E.A.F. Holdings Group Llc |
Alpha polyglutamated aminopterin and uses thereof
|
|
JP7491572B2
(ja)
|
2018-02-07 |
2024-05-28 |
エル．イー．エー．エフ． ホールディングス グループ エルエルシー |
アルファポリグルタミン酸化ペメトレキセドおよびその使用
|
|
EP3749314A4
(en)
|
2018-02-07 |
2022-02-23 |
L.E.A.F Holdings Group LLC |
ALPHA-POLYGLUTAMATE METHOTREXATE AND ITS USES
|
|
JP7462950B2
(ja)
|
2018-02-14 |
2024-04-08 |
エル．イー．エー．エフ． ホールディングス グループ エルエルシー |
ガンマポリグルタミン酸化メトトレキセートおよびその使用
|
|
CA3090753A1
(en)
|
2018-02-14 |
2019-08-22 |
L.E.A.F. Holdings Group Llc |
Gamma polyglutamated pralatrexate and uses thereof
|
|
WO2019160734A1
(en)
|
2018-02-14 |
2019-08-22 |
L.E.A.F. Holdings Group Llc |
Gamma polyglutamated lometrexol and uses thereof
|
|
US12350271B2
(en)
|
2018-02-14 |
2025-07-08 |
L.E.A.F. Holdings Group Llc |
Gamma polyglutamated aminopterin and uses thereof
|
|
EP3775211B1
(en)
|
2018-04-12 |
2023-04-05 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
JP7355394B2
(ja)
|
2018-05-03 |
2023-10-03 |
エル．イー．エー．エフ． ホールディングス グループ エルエルシー |
カロテノイド組成物およびその使用
|
|
MY208145A
(en)
|
2018-06-18 |
2025-04-18 |
Res Inst Nationwide Childrens Hospital |
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
|
|
JP2021532815A
(ja)
|
2018-08-07 |
2021-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
新規Ｃａｓ１２ｂ酵素およびシステム
|
|
EP3833762A4
(en)
|
2018-08-09 |
2022-09-28 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
|
US12421507B2
(en)
|
2018-08-20 |
2025-09-23 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of CRISPR-CAS9
|
|
WO2020061295A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
CA3113025A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
IL281615B2
(en)
|
2018-09-21 |
2026-01-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
EP3856757A4
(en)
|
2018-09-28 |
2022-06-29 |
Nutcracker Therapeutics, Inc. |
Tertiary amino lipidated cationic peptides for nucleic acid delivery
|
|
HRP20240586T1
(hr)
|
2018-10-09 |
2024-07-19 |
The University Of British Columbia |
Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima
|
|
CA3116576A1
(en)
|
2018-10-18 |
2020-04-23 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
KR20210105889A
(ko)
|
2018-11-09 |
2021-08-27 |
아뷰터스 바이오파마 코포레이션 |
지질 나노입자 제제
|
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
|
BR112021009422A2
(pt)
|
2018-12-21 |
2021-10-26 |
Curevac Ag |
Rna para vacinas contra malária
|
|
PT3908568T
(pt)
|
2019-01-11 |
2024-09-30 |
Acuitas Therapeutics Inc |
Lípidos para a administração de agentes ativos por nanopartículas lipídicas
|
|
US20220133908A1
(en)
|
2019-02-08 |
2022-05-05 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
|
|
US12534714B2
(en)
|
2019-03-18 |
2026-01-27 |
The Broad Institute, Inc. |
Type VII CRISPR proteins and systems
|
|
EP3953473A1
(en)
|
2019-04-12 |
2022-02-16 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
WO2020236972A2
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
|
EP3980533A1
(en)
|
2019-06-07 |
2022-04-13 |
Scribe Therapeutics Inc. |
Engineered casx systems
|
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
|
EP3999097B1
(en)
|
2019-07-18 |
2024-05-29 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Rac2 mutant for use in ablating hematopoiesis and in the treatment of hematopoietic malignancies
|
|
JP7759311B2
(ja)
|
2019-07-19 |
2025-10-23 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
リコンビナーゼ組成物及び使用方法
|
|
US20230000997A1
(en)
|
2019-08-06 |
2023-01-05 |
L.E.A.F. Holdings Group Llc |
Processes of preparing polyglutamated antifolates and uses of their compositions
|
|
CN114502204A
(zh)
|
2019-08-14 |
2022-05-13 |
库尔维科公司 |
具有降低的免疫刺激性质的rna组合和组合物
|
|
CN114901253A
(zh)
|
2019-08-14 |
2022-08-12 |
爱康泰生治疗公司 |
用于递送核酸的改进的脂质纳米颗粒
|
|
CN110564729A
(zh)
*
|
2019-09-17 |
2019-12-13 |
四川大学 |
一种对PLK1基因具有沉默活性且具有高血清稳定性的siRNA及其应用
|
|
CA3155015A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2020350759A1
(en)
|
2019-09-19 |
2022-03-31 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP4048807A1
(en)
|
2019-09-23 |
2022-08-31 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein b (apob) gene expression
|
|
CN114729376A
(zh)
|
2019-09-23 |
2022-07-08 |
欧米茄治疗公司 |
用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法
|
|
KR20220144416A
(ko)
|
2020-02-04 |
2022-10-26 |
큐어백 아게 |
코로나바이러스 백신
|
|
KR20230004456A
(ko)
|
2020-03-04 |
2023-01-06 |
리제너론 파아마슈티컬스, 인크. |
면역 요법에 대한 종양 세포의 감작화를 위한 방법 및 조성물
|
|
CA3173528A1
(en)
|
2020-03-11 |
2021-09-16 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
US20230138409A1
(en)
|
2020-03-24 |
2023-05-04 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
|
JP2023520763A
(ja)
|
2020-03-24 |
2023-05-19 |
ジェネレーション バイオ カンパニー |
ゴーシェ治療薬を発現するための非ウイルス性ｄｎａベクター及びその使用
|
|
IL296781A
(en)
|
2020-03-30 |
2022-11-01 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
IL298362A
(en)
|
2020-05-20 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Coronavirus antigen compositions and their uses
|
|
EP4153223A1
(en)
|
2020-05-20 |
2023-03-29 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
|
KR20230029685A
(ko)
|
2020-05-29 |
2023-03-03 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
Trem 조성물 및 이에 관련된 방법
|
|
WO2021243301A2
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
|
CA3170740A1
(en)
|
2020-05-29 |
2021-12-02 |
Curevac Ag |
Nucleic acid based combination vaccines
|
|
IL299094A
(en)
|
2020-06-15 |
2023-02-01 |
Res Inst Nationwide Childrens Hospital |
Administration of an adeno-associated virus vector for muscular dystrophies
|
|
WO2025056938A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
ES3054438T3
(en)
|
2020-07-16 |
2026-02-03 |
Acuitas Therapeutics Inc |
Cationic lipids for use in lipid nanoparticles
|
|
JP2023535632A
(ja)
|
2020-07-27 |
2023-08-18 |
アンジャリウム バイオサイエンシズ エージー |
Ｄｎａ分子の組成物、その作製方法、及びその使用方法
|
|
WO2022023559A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
|
MA71659A
(fr)
|
2020-08-06 |
2025-05-30 |
Modernatx, Inc. |
Compositions pour l'administration de molécules de charge utile à l'épithélium des voies respiratoires
|
|
EP4157344A2
(en)
|
2020-08-31 |
2023-04-05 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
|
AU2021336976A1
(en)
|
2020-09-03 |
2023-03-23 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
JP2023549011A
(ja)
|
2020-09-15 |
2023-11-22 |
ヴァーヴ・セラピューティクス，インコーポレーテッド |
遺伝子編集のための脂質製剤
|
|
CZ310613B6
(cs)
|
2020-09-23 |
2026-01-28 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
EP4228658A4
(en)
|
2020-10-14 |
2025-02-19 |
George Mason Research Foundation, Inc. |
IONIZABLE LIPIDS AND METHODS FOR THE PRODUCTION AND USE THEREOF
|
|
WO2022099003A1
(en)
|
2020-11-06 |
2022-05-12 |
Sanofi |
Lipid nanoparticles for delivering mrna vaccines
|
|
WO2022115645A1
(en)
|
2020-11-25 |
2022-06-02 |
Akagera Medicines, Inc. |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
|
KR20230128289A
(ko)
|
2020-12-03 |
2023-09-04 |
스크라이브 테라퓨틱스 인크. |
조작된 클래스 2 유형 v crispr 시스템
|
|
CN117015374A
(zh)
*
|
2020-12-04 |
2023-11-07 |
潮汐疗法公司 |
可电离阳离子脂质和脂质纳米颗粒及其合成和使用方法
|
|
PH12023500013A1
(en)
*
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
US11918643B2
(en)
|
2020-12-22 |
2024-03-05 |
CureVac SE |
RNA vaccine against SARS-CoV-2 variants
|
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
IL303886A
(en)
|
2020-12-23 |
2023-08-01 |
Flagship Pioneering Inc |
Compositions of modified trems and uses thereof
|
|
US20240102065A1
(en)
|
2021-01-27 |
2024-03-28 |
CureVac SE |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
CA3212653A1
(en)
|
2021-03-26 |
2022-09-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
TW202305133A
(zh)
|
2021-03-26 |
2023-02-01 |
英商米納治療有限公司 |
Tmem173 sarna組合物及其使用方法
|
|
CA3171429A1
(en)
|
2021-03-31 |
2022-09-30 |
Alexander SCHWENGER |
Syringes containing pharmaceutical compositions comprising rna
|
|
EP4313109A1
(en)
|
2021-03-31 |
2024-02-07 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
|
DK4319803T3
(da)
|
2021-04-08 |
2025-12-15 |
Vaxthera Sas |
Coronavirusvaccine omfattende et mosaikprotein
|
|
JP2024517427A
(ja)
|
2021-04-20 |
2024-04-22 |
アンジャリウム バイオサイエンシズ エージー |
アミロ－α－１，６－グルコシダーゼ、４－α－グルカノトランスフェラーゼをコードするＤＮＡ分子の組成物、その作製の方法、及びその使用の方法
|
|
US20240216535A1
(en)
|
2021-04-27 |
2024-07-04 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
AU2022264509A1
(en)
|
2021-04-27 |
2023-12-14 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
EP4334446A1
(en)
|
2021-05-03 |
2024-03-13 |
CureVac SE |
Improved nucleic acid sequence for cell type specific expression
|
|
EP4352215A1
(en)
|
2021-06-11 |
2024-04-17 |
LifeEDIT Therapeutics, Inc. |
Rna polymerase iii promoters and methods of use
|
|
EP4367242A2
(en)
|
2021-07-07 |
2024-05-15 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
CZ310443B6
(cs)
|
2021-07-19 |
2025-06-25 |
Ústav organické chemie a biochemie AV ČR, v. v. i. |
Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
|
|
EP4377457A1
(en)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and uses thereof
|
|
WO2023014974A1
(en)
|
2021-08-06 |
2023-02-09 |
University Of Iowa Research Foundation |
Double stranded mrna vaccines
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
US20240398940A1
(en)
|
2021-09-03 |
2024-12-05 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
US20240398933A1
(en)
|
2021-09-03 |
2024-12-05 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
CN118317944A
(zh)
|
2021-09-14 |
2024-07-09 |
雷纳嘉德医疗管理公司 |
非环状脂质及其使用方法
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
MX2024003262A
(es)
|
2021-09-17 |
2024-06-19 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y metodos para producir poliribonucleotidos circulares.
|
|
GB2625500B
(en)
|
2021-09-21 |
2026-04-01 |
Scribe Therapeutics Inc |
Engineered CasX repressor systems
|
|
CA3235625A1
(en)
|
2021-10-18 |
2023-04-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
|
EP4422698A1
(en)
|
2021-10-29 |
2024-09-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
TW202334080A
(zh)
|
2021-11-08 |
2023-09-01 |
美商歐納醫療公司 |
用於遞送環狀聚核苷酸之脂質奈米粒子組合物
|
|
CN118829423A
(zh)
|
2021-11-12 |
2024-10-22 |
摩登纳特斯有限公司 |
用于将有效载荷分子递送至气道上皮的组合物
|
|
JP2024542188A
(ja)
|
2021-11-16 |
2024-11-13 |
セイル バイオメディシンズ インコーポレイテッド |
新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
|
|
JP2024542260A
(ja)
|
2021-11-22 |
2024-11-13 |
セイル バイオメディシンズ インコーポレイテッド |
新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法
|
|
CN118401544A
(zh)
|
2021-11-24 |
2024-07-26 |
旗舰创业创新六公司 |
水痘-带状疱疹病毒免疫原组合物及其用途
|
|
IL312965A
(en)
|
2021-11-24 |
2024-07-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and their uses
|
|
EP4436984A1
(en)
|
2021-11-24 |
2024-10-02 |
Flagship Pioneering Innovations VI, LLC |
Coronavirus immunogen compositions and their uses
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
KR20240118174A
(ko)
|
2021-12-17 |
2024-08-02 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
변성 조건 하에서의 원형 rna의 풍부화를 위한 방법
|
|
EP4453201A1
(en)
|
2021-12-22 |
2024-10-30 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
EP4452928A1
(en)
|
2021-12-23 |
2024-10-30 |
Renagade Therapeutics Management Inc. |
Constrained lipids and methods of use thereof
|
|
KR20240118881A
(ko)
|
2021-12-23 |
2024-08-05 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
항푸소제닉 폴리펩티드를 인코딩하는 원형 폴리리보뉴클레오티드
|
|
JP2025504404A
(ja)
|
2022-01-14 |
2025-02-12 |
アンジャリウム バイオサイエンシズ エージー |
Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法
|
|
JP2025502257A
(ja)
|
2022-01-17 |
2025-01-24 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
固形腫瘍細胞の集団の細胞死を誘導する方法
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
US20250345416A1
(en)
|
2022-01-27 |
2025-11-13 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
US20250099614A1
(en)
|
2022-01-28 |
2025-03-27 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
EP4475882A1
(en)
|
2022-02-09 |
2024-12-18 |
ModernaTX, Inc. |
Mucosal administration methods and formulations
|
|
US20250064899A1
(en)
|
2022-02-14 |
2025-02-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the 15-lipoxygenase for the treatment of lymphedema
|
|
US20250327041A1
(en)
|
2022-02-24 |
2025-10-23 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
CN119072330A
(zh)
|
2022-03-14 |
2024-12-03 |
世代生物公司 |
异源初免加强疫苗组合物和使用方法
|
|
WO2023178425A1
(en)
|
2022-03-23 |
2023-09-28 |
Nanovation Therapeutics Inc. |
High sterol-containing lipid nanoparticles
|
|
KR20240166554A
(ko)
|
2022-03-25 |
2024-11-26 |
세일 바이오메디슨스, 인크. |
신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
|
|
WO2023184038A1
(en)
|
2022-04-01 |
2023-10-05 |
Nanovation Therapeutics Inc. |
Mrna delivery method and composition thereof
|
|
IL316038A
(en)
|
2022-04-04 |
2024-11-01 |
Univ California |
Preparations and methods for genetic complementation
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
|
AU2023260227A1
(en)
|
2022-04-27 |
2024-11-21 |
Shanghai Regenelead Therapies Co., Ltd |
Nucleic acid construct and use thereof
|
|
CA3257006A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS
|
|
AU2023268051A1
(en)
|
2022-05-13 |
2025-01-02 |
BioNTech SE |
Rna compositions targeting hiv
|
|
TW202409283A
(zh)
|
2022-05-13 |
2024-03-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
雙股ｄｎａ組合物及相關方法
|
|
TW202400784A
(zh)
|
2022-05-13 |
2024-01-01 |
大陸商上海瑞宏迪醫藥有限公司 |
包含utr的核酸構建體及其應用
|
|
JP2025522297A
(ja)
|
2022-05-25 |
2025-07-15 |
ビオンテック エスエー |
サルポックス抗原の送達のためのｒｎａ組成物及び関連する方法
|
|
CA3256897A1
(en)
|
2022-05-25 |
2023-11-30 |
Akagera Medicines, Inc. |
Lipid nanoparticles for the administration of nucleic acids and their methods of use
|
|
US20250345407A1
(en)
|
2022-05-25 |
2025-11-13 |
CureVac SE |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
|
JP2025518221A
(ja)
|
2022-05-30 |
2025-06-12 |
ビオンテック・ソシエタス・エウロパエア |
核酸の送達のための複合体
|
|
WO2023235818A2
(en)
|
2022-06-02 |
2023-12-07 |
Scribe Therapeutics Inc. |
Engineered class 2 type v crispr systems
|
|
TW202413643A
(zh)
|
2022-06-07 |
2024-04-01 |
美商斯奎柏治療公司 |
用於靶向pcsk9的組合物及方法
|
|
GB2634837A
(en)
|
2022-06-07 |
2025-04-23 |
Scribe Therapeutics Inc |
Compositions and methods for the targeting of PCSK9
|
|
EP4536197A1
(en)
|
2022-06-07 |
2025-04-16 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
|
US20250179492A1
(en)
|
2022-06-22 |
2025-06-05 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
AU2023316015A1
(en)
|
2022-07-25 |
2025-02-13 |
Centre Hospitalier Universitaire De Toulouse |
Use of apelin for the treatment of lymphedema
|
|
EP4565604A2
(en)
|
2022-08-01 |
2025-06-11 |
Flagship Pioneering Innovations VII, LLC |
Immunomodulatory proteins and related methods
|
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
EP4569093A1
(en)
|
2022-08-12 |
2025-06-18 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
US20260055426A1
(en)
|
2022-08-19 |
2026-02-26 |
Generation Bio Co. |
CLEAVABLE CLOSED-ENDED DNA (ceDNA) AND METHODS OF USE THEREOF
|
|
US20260060926A1
(en)
|
2022-08-31 |
2026-03-05 |
Sail Biomedicines, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
WO2024047247A1
(en)
|
2022-09-02 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for the treatment of amyotrophic lateral sclerosis
|
|
EP4342460A1
(en)
|
2022-09-21 |
2024-03-27 |
NovoArc GmbH |
Lipid nanoparticle with nucleic acid cargo
|
|
WO2024064931A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of liver stage antigens and related methods
|
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
|
IL319704A
(en)
|
2022-09-23 |
2025-05-01 |
Nchroma Bio Inc |
Compositions and methods for epigenetic regulation of HBV gene expression
|
|
JP2025533527A
(ja)
|
2022-09-23 |
2025-10-07 |
ビオンテック・ソシエタス・エウロパエア |
Ｐｌａｓｍｏｄｉｕｍ ＣＳＰ抗原の送達のための組成物及び関連方法
|
|
AU2023353931A1
(en)
|
2022-09-26 |
2025-03-20 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
US20240174732A1
(en)
|
2022-10-05 |
2024-05-30 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
|
|
WO2024074211A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
WO2024074634A1
(en)
|
2022-10-06 |
2024-04-11 |
BioNTech SE |
Rna compositions targeting claudin-18.2
|
|
EP4608442A1
(en)
|
2022-10-28 |
2025-09-03 |
GlaxoSmithKline Biologicals S.A. |
Nucleic acid based vaccine
|
|
EP4612296A1
(en)
|
2022-10-31 |
2025-09-10 |
Flagship Pioneering Innovations VI, LLC |
Compositions and methods for purifying polyribonucleotides
|
|
WO2024102677A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
TW202434728A
(zh)
|
2022-11-08 |
2024-09-01 |
美商旗艦先鋒創新有限責任公司 |
用於產生環狀多核糖核苷酸的組成物和方法
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024119074A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
EP4626400A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
AU2023406303A1
(en)
|
2022-12-01 |
2025-05-29 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses
|
|
EP4630057A1
(en)
|
2022-12-08 |
2025-10-15 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2024121378A1
(en)
|
2022-12-09 |
2024-06-13 |
Institut National de la Santé et de la Recherche Médicale |
Novel human antiviral genes related to the eleos and lamassu prokaryotic systems
|
|
WO2024125597A1
(en)
|
2022-12-14 |
2024-06-20 |
Providence Therapeutics Holdings Inc. |
Compositions and methods for infectious diseases
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
EP4642797A1
(en)
|
2022-12-28 |
2025-11-05 |
BioNTech SE |
Rna compositions targeting hiv
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024151583A2
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
|
JP2026503277A
(ja)
|
2023-01-09 |
2026-01-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
心筋梗塞を経験した患者における有害な虚血後心臓リモデリングを処置するためのアンジオポエチン様４の組み換えフィブリノーゲン様ドメインの使用
|
|
WO2024153636A1
(en)
|
2023-01-17 |
2024-07-25 |
Institut National de la Santé et de la Recherche Médicale |
Vasorin as a biomarker and biotarget in nephrology
|
|
JP2026503627A
(ja)
|
2023-01-27 |
2026-01-29 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
血管透過性亢進の処置方法におけるアンフィレグリン（ａｒｅｇ）の使用
|
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
|
WO2024167885A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
|
CN121263425A
(zh)
|
2023-02-13 |
2026-01-02 |
旗舰创业创新第七有限责任公司 |
含可裂解接头的可电离脂质和用于治疗性组合物的脂质载体
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
IL322378A
(en)
|
2023-02-17 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
DNA compositions containing modified cytosine
|
|
EP4665405A1
(en)
|
2023-02-17 |
2025-12-24 |
Flagship Pioneering Innovations VII, LLC |
Dna compositions comprising modified uracil
|
|
WO2024184500A1
(en)
|
2023-03-08 |
2024-09-12 |
CureVac SE |
Novel lipid nanoparticle formulations for delivery of nucleic acids
|
|
CN121358494A
(zh)
|
2023-03-15 |
2026-01-16 |
旗舰创业创新第六有限责任公司 |
免疫原性组合物及其用途
|
|
EP4680750A1
(en)
|
2023-03-15 |
2026-01-21 |
Flagship Pioneering Innovations VI, LLC |
Compositions comprising polyribonucleotides and uses thereof
|
|
WO2024194484A1
(en)
|
2023-03-23 |
2024-09-26 |
Institut National de la Santé et de la Recherche Médicale |
Modulating the expression and/or activity of gas7 for modulating viral replication
|
|
PE20252746A1
(es)
|
2023-03-29 |
2025-12-05 |
Scribe Therapeutics Inc |
Composiciones y metodos para el direccionamiento a pcsk9
|
|
WO2024206676A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of lpa
|
|
WO2024206620A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Messenger rna encoding casx
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024206565A1
(en)
|
2023-03-29 |
2024-10-03 |
Scribe Therapeutics Inc. |
Repressor fusion protein systems
|
|
EP4695393A1
(en)
|
2023-04-12 |
2026-02-18 |
Flagship Pioneering Innovations VI, LLC |
Modified trems, compositions, and related methods thereof
|
|
EP4695391A1
(en)
|
2023-04-12 |
2026-02-18 |
Flagship Pioneering Innovations VI, LLC |
Trems for use in correction of missense mutations
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
AU2024260120A1
(en)
|
2023-04-27 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024228150A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024228044A1
(en)
|
2023-05-03 |
2024-11-07 |
BioNTech SE |
Optimized csp variants and related methods
|
|
WO2024229309A2
(en)
|
2023-05-03 |
2024-11-07 |
Manifold Biotechnologies, Inc. |
Methodsand compositions for high-throughput protein delivery, screening, and detection
|
|
EP4705481A2
(en)
|
2023-05-05 |
2026-03-11 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
WO2024238700A1
(en)
|
2023-05-15 |
2024-11-21 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
EP4716741A2
(en)
|
2023-05-23 |
2026-04-01 |
Flagship Labs 114, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
WO2025024324A1
(en)
|
2023-07-21 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
IL325865A
(en)
|
2023-07-21 |
2026-03-01 |
BioNTech SE |
Compositions for administering Plasmodium antigens and related methods
|
|
WO2025021083A1
(en)
*
|
2023-07-24 |
2025-01-30 |
National Institute Of Biological Sciences, Beijing |
Lipid nanoparticle compositions for localized treatment of skin diseases
|
|
WO2025024337A1
(en)
|
2023-07-24 |
2025-01-30 |
BioNTech SE |
Compositions for delivery of plasmodium antigens and related methods
|
|
KR20260044217A
(ko)
|
2023-07-25 |
2026-04-01 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
Cas 엔도뉴클레아제 및 관련 방법
|
|
WO2025022367A2
(en)
|
2023-07-27 |
2025-01-30 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
|
WO2025027089A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thiolipids and uses thereof
|
|
WO2025026545A1
(en)
|
2023-08-01 |
2025-02-06 |
BioNTech SE |
Ionizable thioplipids and uses thereof
|
|
WO2025030154A1
(en)
|
2023-08-03 |
2025-02-06 |
The Trustees Of The University Of Pennsylvania |
Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
|
|
WO2025027579A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Rna compositions targeting hiv
|
|
CN121866336A
(zh)
|
2023-08-03 |
2026-04-14 |
百欧恩泰欧洲股份公司 |
靶向hiv的rna组合物
|
|
WO2025030097A2
(en)
|
2023-08-03 |
2025-02-06 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
IL326647A
(en)
|
2023-09-01 |
2026-04-01 |
Novoarc Gmbh |
Lipid nanoparticles with a nucleic acid charge and an ionizable lipid
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
EP4520345A1
(en)
|
2023-09-06 |
2025-03-12 |
Myneo Nv |
Product
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025054556A1
(en)
|
2023-09-07 |
2025-03-13 |
BioNTech SE |
Rna compositions for delivery of mpox antigens and related methods
|
|
WO2025057088A1
(en)
|
2023-09-11 |
2025-03-20 |
BioNTech SE |
Rna compositions for delivery of incretin agents
|
|
WO2025064475A2
(en)
|
2023-09-18 |
2025-03-27 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
WO2025072383A1
(en)
|
2023-09-25 |
2025-04-03 |
The Broad Institute, Inc. |
Viral open reading frames, uses thereof, and methods of detecting the same
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025072293A1
(en)
|
2023-09-27 |
2025-04-03 |
Scribe Therapeutics Inc. |
Optimized mrnas encoding casx proteins
|
|
AU2024357861A1
(en)
|
2023-10-12 |
2026-04-23 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025083619A1
(en)
|
2023-10-18 |
2025-04-24 |
Life Edit Therapeutics, Inc. |
Rna-guided nucleases and acive fragments and variants thereof and methods of use
|
|
WO2025083211A1
(en)
|
2023-10-20 |
2025-04-24 |
Institut National de la Santé et de la Recherche Médicale |
Use of factor h for the treatment of dementia
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
WO2025106670A1
(en)
|
2023-11-14 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Ionizable lipidoid compositions and therapeutic uses thereof
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
US12553042B2
(en)
|
2023-12-01 |
2026-02-17 |
Recode Therapeutics, Inc. |
Method for quantifying an amount of capped messenger RNA
|
|
US12364773B2
(en)
|
2023-12-01 |
2025-07-22 |
Recode Therapeutics, Inc. |
Lipid nanoparticle compositions and uses thereof
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025124711A1
(en)
|
2023-12-13 |
2025-06-19 |
BioNTech SE |
Glycolipid compositions
|
|
WO2025129158A1
(en)
|
2023-12-15 |
2025-06-19 |
The Broad Institute, Inc. |
Engineered arc delivery vesicles and uses thereof
|
|
WO2025129128A1
(en)
|
2023-12-15 |
2025-06-19 |
Vivasor, Inc. |
Compositions and methods for non-viral delivery of therapeutic compounds
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025134062A2
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025134066A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Ionizable lipids
|
|
WO2025133105A1
(en)
|
2023-12-21 |
2025-06-26 |
Biontech Delivery Technologies Gmbh |
Compositions and methods
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
TW202545974A
(zh)
|
2024-01-26 |
2025-12-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
免疫受體抑制蛋白及相關方法
|
|
WO2025166325A1
(en)
|
2024-02-02 |
2025-08-07 |
Editas Medicine, Inc. |
MODIFIED GUIDE RNAs
|
|
WO2025174908A1
(en)
|
2024-02-12 |
2025-08-21 |
Life Edit Therapeutics, Inc. |
Novel rna-guided nucleases and proteins for polymerase editing
|
|
WO2025184508A1
(en)
|
2024-03-01 |
2025-09-04 |
Acuitas Therapeutics, Inc. |
Materials and methods for encapsulating therapeutics in lipid nanoparticles
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025213138A1
(en)
|
2024-04-05 |
2025-10-09 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
|
|
WO2025213131A1
(en)
|
2024-04-05 |
2025-10-09 |
BioNTech SE |
Rna compositions for delivery of orthopox antigens and related methods
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
WO2025215072A1
(en)
|
2024-04-10 |
2025-10-16 |
Institut National de la Santé et de la Recherche Médicale |
Class i lanthipeptides with anti-viral function
|
|
US20250353881A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025240940A1
(en)
|
2024-05-17 |
2025-11-20 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of apolipoprotein c3
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025250808A1
(en)
|
2024-05-29 |
2025-12-04 |
The Brigham And Women’S Hospital, Inc. |
Anti-crispr delivery compositions and methods
|
|
WO2025248096A1
(en)
|
2024-05-31 |
2025-12-04 |
Institut National de la Santé et de la Recherche Médicale |
Antimicrobial peptides having liquid-liquid phase separation activities
|
|
WO2025259931A1
(en)
|
2024-06-14 |
2025-12-18 |
Orbital Therapeutics, Inc. |
Compositions and methods for rna circularization
|
|
WO2025262460A1
(en)
|
2024-06-21 |
2025-12-26 |
BioNTech SE |
Lipid compositions for nucleic acid delivery
|
|
WO2026006203A2
(en)
|
2024-06-24 |
2026-01-02 |
Orbital Therapeutics, Inc. |
Compositions and methods for making circular rna
|
|
WO2026003754A1
(en)
|
2024-06-25 |
2026-01-02 |
Life Edit Therapeutics, Inc. |
Novel reverse transcriptases and uses thereof
|
|
US20260000702A1
(en)
|
2024-06-26 |
2026-01-01 |
Flagship Pioneering Innovations Vii, Llc |
Therapeutic circular dna forms
|
|
WO2026003582A2
(en)
|
2024-06-27 |
2026-01-02 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2026015882A1
(en)
|
2024-07-12 |
2026-01-15 |
BioNTech SE |
Hsv antigen fragments and related methods
|
|
WO2026018213A1
(en)
|
2024-07-18 |
2026-01-22 |
Vaxthera Sas |
A broadly protective mosaic vaccine against highly pathogenic avian influenza viruses
|
|
WO2026020171A2
(en)
|
2024-07-19 |
2026-01-22 |
Aera Therapeutics, Inc. |
Chimeric antigen receptor constructs
|
|
WO2026027887A2
(en)
|
2024-08-02 |
2026-02-05 |
Mina Therapeutics Limited |
Hbg1/2-sarna compositions and methods of use
|
|
WO2026055543A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Modified dna compositions and related methods
|
|
WO2026055547A1
(en)
|
2024-09-06 |
2026-03-12 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions and related methods
|
|
WO2026064313A1
(en)
|
2024-09-17 |
2026-03-26 |
Flagship Pioneering Innovations Vii, Llc |
Rna compositions and related methods
|
|
WO2026064512A1
(en)
|
2024-09-18 |
2026-03-26 |
Generation Bio Co. |
Polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
WO2026085300A1
(en)
|
2024-10-16 |
2026-04-23 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods
|
|
WO2026085495A1
(en)
|
2024-10-18 |
2026-04-23 |
Generation Bio Co. |
Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor
|